bathocuproine disulfonate has been researched along with Alzheimer Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, Q; Lang, M; Wang, L; Wang, W; Wang, X; Xiao, G; Zheng, Y; Zhong, Y; Zhou, B | 1 |
| Barnham, KJ; Beyreuther, K; Bush, AI; Cherny, RA; Li, QX; Lynch, T; Masters, CL; McLean, CA; Multhaup, G; Tanzi, RE; Volitakis, I | 1 |
2 other study(ies) available for bathocuproine disulfonate and Alzheimer Disease
| Article | Year |
|---|---|
Inhibition of human high-affinity copper importer Ctr1 orthologous in the nervous system of Drosophila ameliorates Aβ42-induced Alzheimer's disease-like symptoms.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Cation Transport Proteins; Cell Count; Chelating Agents; Conditioning, Classical; Copper Transporter 1; Disease Models, Animal; Drosophila; Drosophila Proteins; Gene Expression Regulation; Humans; Locomotion; Longevity; Male; Memory Disorders; Nerve Degeneration; Nervous System; Oxidative Stress; Peptide Fragments; Phenanthrolines; RNA Interference; Time Factors | 2013 |
Chelation and intercalation: complementary properties in a compound for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Chelating Agents; Copper; Humans; Mice; Mice, Transgenic; Nuclear Magnetic Resonance, Biomolecular; Penicillamine; Peptides; Phenanthrolines; Pilot Projects; Solubility; Trientine; Zinc | 2000 |